USA - NASDAQ:ISRG - US46120E6023 - Common Stock
The current stock price of ISRG is 546.51 USD. In the past month the price increased by 23.89%. In the past year, price increased by 6.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.02 | 53.26B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B | ||
| STE | STERIS PLC | 25.24 | 23.71B |
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
INTUITIVE SURGICAL INC
1020 Kifer Road
Sunnyvale CALIFORNIA 94086 US
CEO: Gary S. Guthart
Employees: 15638
Phone: 14085232100
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
The current stock price of ISRG is 546.51 USD. The price decreased by -0.87% in the last trading session.
ISRG does not pay a dividend.
ISRG has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
INTUITIVE SURGICAL INC (ISRG) has a market capitalization of 195.91B USD. This makes ISRG a Large Cap stock.
INTUITIVE SURGICAL INC (ISRG) will report earnings on 2026-01-21, after the market close.
The outstanding short interest for INTUITIVE SURGICAL INC (ISRG) is 2.07% of its float.
ChartMill assigns a technical rating of 6 / 10 to ISRG. When comparing the yearly performance of all stocks, ISRG turns out to be only a medium performer in the overall market: it outperformed 62.84% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to ISRG. ISRG gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months ISRG reported a non-GAAP Earnings per Share(EPS) of 8.61. The EPS increased by 28.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.51% | ||
| ROA | 12.93% | ||
| ROE | 14.61% | ||
| Debt/Equity | 0 |
40 analysts have analysed ISRG and the average price target is 597.45 USD. This implies a price increase of 9.32% is expected in the next year compared to the current price of 546.51.
For the next year, analysts expect an EPS growth of 13.5% and a revenue growth 19.68% for ISRG